|
Interesting point.
Just a small correction, the Anthropic stake is higher. ($13B + another $20B option if they hit certain milestones, which I believe is almost guaranteed) So it's closer to $33B In any case, there is no reason for them to purposefully hurt Anthropic. I would say that this government "takedown" of Mythos is great free advertising. I mean, if you look at this, they said it's too risky to launch, we all said it's pure marketing, and now when it's actually "banned" for being too risky, we laugh at the "Karma", where in fact, the majority of people who are not in our circles, see it as "wow, they were not kidding". The overall result is net gain in brand awareness to Anthropic, before an IPO, I think if we had 2 parallel universes with or without this ban, the one with is a much higher IPO outcome for Anthropic than the other. And again, I think this all needs to be taken with Occam's razor and bit of Hanlon's razor (without going into politics, the technical savviness of this administration is not the thing it's most famous for) |
Now, say you don't want to sign a pre-committed enterprise contract with Anthropic. But oh, you already have such a contract with AWS, and they'll let you use any model you want, and they've implemented KYC and will graciously connect you with a solutions partner who can help you with the IAM systems integrations for key tracking and attribution.
Oh, and all these enterprise contracts will bill by token. We're not talking a small stake in a company selling subscriptions, we're talking immediate revenue at four-figure-per-user levels, and pushing more and more companies to see that as "just part of their AWS bill."
This is worth a significant amount of money to AWS. So the question is: does Hanlon's Razor apply when a $2.5 trillion company is putting its best minds into how to engineer strategic outcomes?
The regulatory capture angle here is, if anything, an implementation detail.